

# 5<sup>th</sup> edition

## PROVISIONAL PROGRAM

15 rue de l'École de Médecine 75006 Paris, France

**Tuesday September 14<sup>th</sup> 2021**

### 13.25-13.30 OPENING

Welcome and introduction: Pr Eric Deutsch, Head of Gustave Roussy Radiation Oncology Department, FR / conference co-chair

PRIMER ON CANCER IMMUNOLOGY, RADIATIONS, DNA DAMAGE AND IMMUNOTHERAPY  
(Educational Session CME accredited)

### 13.30-15.30 Part I

#### Cancer Immunology and Immunotherapy

🕒 13.30 -14.00

Intercellular communication within the immune system

Pr Vassili Soumelis, IUH Saint-Louis 

🕒 14.00 -14.30

Microbiota-Centered Interventions : data and prospects

Dr Lisa Derosa, Gustave Roussy 

🕒 14.30 -15.00

Beneficial autoimmunity dictates the prognosis of cancer therapy

Pr Guido Kroemer, Cordeliers Research Center 

🕒 15.00 -15.30

Clinical immunotherapy in melanoma

Pr Caroline Robert, Gustave Roussy 

15.30-16.00 Coffee break

### 16.00-18.00 Part II

#### Radiations, DNA Damage and Cancer Immunotherapy

🕒 16.00 -16.30

Mutations and the Basis of How T Cells Recognize Tumor Cells

Pr Timothy Chan, Case Comprehensive Cancer Center 

🕒 16.30 -17.00

Modulation of cancer cells antigenicity by radiation

Pr Sandra Demaria, Weill Cornell Medicine 

🕒 17.00 -17.30

Harnessing radiotherapy to boost the efficacy of cancer (immune)therapy

Dr Lorenzo Galluzzi, Weill Cornell Medicine 

🕒 17.30 -18.00

New Targeted Therapies to Enhance Radiation and Immune Interactions

Pr Amato Giaccia, Oxford Institute for Radiation Oncology 

Poster session

## Wednesday September 15<sup>th</sup> 2021

MAIN PROGRAM

### 8.30-10.00 Session I

Radiation Response


🕒 8.30 -9.00

Normal tissue toxicity in the era of radiotherapy/immunotherapy combinations : preclinical challenges

Dr Fabien Millat, IRSN 


🕒 9.00 -9.30

TRIM33 as a myeloid interferon checkpoint : from molecular mechanism to radiotherapy improvement

Dr Germain Rousselet, CEA 

🕒 9.30 -10.00

The microbiome impact on normal tissue radiation response

Dr Antonin Levy, Gustave Roussy 

10.00-10.30 Coffee break

### 10.30-12.30 Session II

Impact of Mutations

🕒 10.30 -11.00

New insights into the mutational processes and the landscape driver mutations of Basal Cell Carcinoma of skin from Whole Genome Sequencing

Dr Sergey Nikolaev, Gustave Roussy 

🕒 11.00 -11.30

DNA repair defects in cancer affecting the response to immunotherapy

Pr Simon Powell, MSKCC 

🕒 11.30 -12.00

Mutational load and immunogenicity of gliomas

Dr Mehdi Touat, La Pitié Salpêtrière 

🕒 12.00 -12.30

TBD

12.30-13.30 Lunch break and exhibition

### 14.00-16.00 Session III

Immune Contexture

🕒 14.00 -14.30

The immune contexture in the era of cancer immunotherapies

Dr Jerome Galon, Cordeliers Research Center 

🕒 14.30 -15.00

Immune signatures for characterization and prediction of responses of solid tumors to treatments with immune therapies and radiotherapy

Pr Udo Gaipl, Friedrich-Alexander University Erlangen-Nürnberg 


🕒 15.00 -15.30

Targeting lipid metabolism to generate anti-tumor immunity in irradiated glioblastoma

Dr Claire Vanpouille-Box, Weill Cornell Medicine 

🕒 15.30 -16.00

Can we predict response to immunotherapy in lung cancers?

Pr Fabrice Barlési, Gustave Roussy 

16.00-16.30 coffee break

## 16.30-18.00 Session IV

### Cell Death


🕒 16.30 -17.00

Ionizing radiation results in a mixture of cellular outcomes including mitotic catastrophe, senescence, methuosis, and iron-dependent cell death

Pr Peter Vandenabeele, Ghent University 

🕒 17.00 -17.30

Ferroptosis and radiation-associated tumor immunity

Pr Weiping Zou, University of Michigan 

🕒 17.30 -18.00

TBD

# Thursday September 16<sup>th</sup> 2021

## 8.30-10.00 Session V

### Immunosuppression

🕒 8.30 -9.00

The role of cancer-associated fibroblasts and the extracellular matrix in the tumour response to radiotherapy

Dr Anna Wilkins, ICR 

🕒 9.00 -9.30

The (TER)rible TER cells: do these cells effect radiotherapy and immunotherapy?

Pr Ralph Weichselbaum, University of Chicago 

🕒 9.30 -10.00

Role of stromal heterogeneity in immunosuppression and immunotherapy resistance

Dr Fatima Mechta-Grigoriou, Institut Curie 


10.00-10.30 Coffee break

## 10.30-12.30 Session VI

### Innate Immunity


🕒 10.30 -11.00

Macrophage Ontogeny and Biology

Dr Florent Ginhoux, Gustave Roussy 


🕒 11.00 -11.30

Macrophage involvement in tissue responses to radiation in cancer and non-cancer pathologies

Dr Lydia Meziani, Gustave Roussy 

🕒 11.30 -12.00

Harnessing innate immunity in cancer therapy and beyond

Pr Eric Vivier, CIML 

🕒 12.00 -12.30

Harnessing innate immunity for radiation therapy

Dr Jean-Luc Perfettini, Gustave Roussy 

12.30-14.00 Lunch break and exhibition

## 14.00-16.00 Session VII

### Artificial Intelligence

🕒 14.00 -14.30

Radiomics for predicting response to immunotherapy

Dr Roger Sun, Gustave Roussy 


🕒 14.30 -15.00

Machine Learning for radio-immunotherapy

Pr Issam EL-Naqa, Moffit Cancer Center 


🕒 15.00 -15.30

Breast cancer management using next-generation genomics and artificial intelligence

Pr Fabrice André, Gustave Roussy 

🕒 15.30 -16.00

Prospects for next generation radiotherapy at the era of AI and immunotherapy

Pr Eric Deutsch, Gustave Roussy 

16.00-16.30 Coffee break

## 16.30-18.00 Session VIII

### Adaptive Immunity

🕒 16.30 -17.00

Adoptive T cell therapy in solid tumors

Pr George Coukos, CHUV 

🕒 17.00 -17.30

Awakening immune system with radiation: bidirectional translational approach

Dr Maria Esperanza Rodriguez Ruiz, Clínica Universidad de Navarra 

🕒 17.30 -18.00

COVID-19- oncological specificities: what did we learn from virus-specific T cells responses for cancer?


Pr Laurence Zitvogel, Gustave Roussy 

Gala dinner


Friday September 17<sup>th</sup> 2021

**8.30-10.00 Session IX**  
**Immune Communication**


🕒 8.30 -9.00

Targeting IFN-I coupled innate immune receptors for cancer immunotherapy  
Dr Hendrik Poeck, Technische Universität München 

🕒 9.00 -9.30

The GOOD, the ELDER & the BAD: RNA Vaccine & Radiotherapy to fight Cancer  
Dr Fulvia Vascotto, TrOn 

🕒 9.30 -10.00

Unleashing the myeloid cell-dependent interferon response to improve the efficacy of radiotherapy in head and neck tumors, Dr Michele Mondini, Gustave Roussy 

10.00-10.30 Coffee break

**10.30-12.30 Session X**  
**Combinations**

🕒 10.30 -11.00

Immunogenicity of particle therapy and the potential in combination with immunotherapy  
Dr Alexander Helm, Technische Universität Darmstadt 


🕒 11.00 -11.30

Immunotherapy/radiotherapy combinations in head and neck squamous cell carcinoma  
Pr David Raben, University of Colorado 


🕒 11.30 -12.00

Mobilizing anti-tumor immunity with low dose irradiation  
Pr Fernanda Herrera, CHUV 

🕒 12.00 -12.30

Strategies to enhance radiation immunogenicity  
Pr Silvia Formenti, Weill Cornell Medicine 

**Closing and Farewell:**

Pr Silvia Formenti, Weill Cornell Medicine   
conference co-chair

Official Media Partner  
**THE LANCET**  
**Oncology**

